| dc.contributor.author | Dean S Karahalios, Andrea Shaw, Bonnke Arunga, Carlee Lenehan, Valentine Sing'oei, Walter Otieno | |
| dc.date.accessioned | 2022-10-03T13:30:31Z | |
| dc.date.available | 2022-10-03T13:30:31Z | |
| dc.date.issued | 2022-09-09 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/5335 | |
| dc.description | https://www.elsevier.com/locate/mmcr | en_US |
| dc.description.abstract | Subcutaneous phycomycosis becomes a chronic, debilitating condition if left untreated. Treatment includes oral antifungal therapy, though oral potassium iodide has been used in resource-limited settings. Lugol's iodine has been an effective substitute, but little is known about its safety. We report a case of subcutaneous phycomycosis complicated by heart failure during treatment with Lugol's iodine. We review subcutaneous phycomycosis, iodine-mediated cardiotoxicity, as well as social determinants of health relevant to our case, suggesting that Lugol's iodine may only be an effective treatment with proper dosing and long-term monitoring. | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Subcutaneous phycomycosis, Fungal infection, Lugol’s iodine,Heart failure,Social determinants of healt | en_US |
| dc.title | Adverse effects of Lugol’s iodine: Heart failure in a patient with subcutaneous phycomycosis from a resource-limited setting | en_US |
| dc.type | Article | en_US |
